Home > Healthcare & Medical Devices > Autoinjectors Market

Autoinjectors Market Size by Type (Disposable, Reusable), By Route of Administration (Subcutaneous, Intramuscular), By Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Diabetes, Oncology, Asthma, Migraine, Hormone Therapy), By End-use (Hospital & Clinics, Homecare Settings), Regional Outlook, Industry Analysis Report, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032

  • Report ID: GMI5412
  • Published Date: Dec 2022
  • Report Format: PDF

Industry Statistics

Autoinjectors Market size accounted for more than USD 55 billion in 2022 and is expected to record over 13% CAGR from 2023 to 2032. Rising cases of chronic diseases and autoimmune disorders will shape industry trends.
 

Autoinjectors Market

Get more details on this report - Request Free Sample PDF
 

The prevalence of chronic diseases, such as diabetes, anaphylaxis, rheumatoid arthritis, and psoriasis has increased among the global population which has elevated the need for effective treatment solutions and tools like autoinjectors. To improve the quality of life of affected people, medical companies have developed autoinjectors that can deliver a variety of formulations of different treatments and therapies. The demand for focused and targeted therapy may increase the deployment of these devices. The introduction of investments in targeted therapy and novel drugs will further foster industry growth in the coming years.
 

The availability of alternative treatment options may impede the market share. Patients often experience pain and intrusion when receiving medication via injectable routes due to which many individuals choose oral medications. The oral method of drug administration is popular among patients because it is simple, affordable, secure, acceptable, and practical. The introduction of other needle-free medication delivery systems that are easier to administer without pain could limit the autoinjectors market expansion.
 

As per the World Health Organization (WHO), only 50% of people with chronic conditions take their medications as directed by their doctors. Non-adherence negatively affects patient outcomes and considerably drives up healthcare costs. In the United States and Europe, it is estimated that unnecessary healthcare spending amounts to up to USD 290 billion and USD 13 billion respectively. Pharmaceutical companies lose an average of 36% of each drug's potential revenue. This translates into losses for the U.S. pharmaceutical industry alone of roughly USD 188 billion per year.
 

Development of reusable autoinjectors to drive product use for chronic disorder treatments

Autoinjectors Market by Type

Get more details on this report - Request Free Sample PDF
 

Autoinjectors market share from reusable segment is expected to record a 13.9% CAGR over 2023-2032. A remarkable rate of development is observed in reusable autoinjectors along with a variety of doses. One of the key developments in the device manufacturing sector is user-friendly devices for both emergency use and chronic medical disorders. The use of these injectors across multiple verticals has elevated the development and adoption of these devices for chronic disease treatment and emergency cases.
 

Ease of self-injection fueling the demand for subcutaneous autoinjectors

Autoinjectors Market by Route of Administration

Get more details on this report - Request Free Sample PDF
 

Based on the route of administration, autoinjectors market share from the subcutaneous autoinjectors segment is expected to reach over USD 172 billion by end of 2032. Autoinjectors come in a variety of forms, from simple push-on-the-skin gadgets to fully automated button-activated systems. There are many autoinjectors available as an alternative to manual syringes for the subcutaneous administration of drugs for various conditions. These devices have increased patient compliance and adherence because they allow patients to self-inject their drugs.
 

Rise in cases of anaphylaxis to influence the demand for autoinjectors

Autoinjectors Market by Therapy

Get more details on this report - Request Free Sample PDF
 

Autoinjectors market share from anaphylaxis therapy segment is forecasted to reach over USD 10 billion by 2032 owing to the rising prevalence and occurrence of anaphylaxis and food allergies. According to a recent survey, around 10% of the world's population has a food allergy, and the number of such allergies continues to rise annually. This therapy for anaphylaxis must be administered within 30 minutes as the condition can be fatal. Since epinephrine is the recommended treatment for anaphylaxis, the development of autoinjectors for it has skyrocketed.
 

Higher investments in product development to shape Middle East and Africa market expansion

Autoinjectors Market by Region

Get more details on this report - Request Free Sample PDF
 

Middle East & Africa autoinjectors market value is expected to reach over USD 12 billion by 2032. Demand for therapy using autoinjectors will increase as chronic diseases like cancer and autoimmune diseases become more prevalent. The potential for industry expansion will be fueled by significant investments made in the development of new products by medical firms operating in the region. Several medical equipment manufacturers are concentrating on investing in the biologics sector to expand their product portfolio in the native market.
 

Launch of new products to complement global autoinjectors industry outlook

AbbVie Inc., GlaxoSmithKline Plc., Mylan, Amgen, Becton, Ypsomed, Dickinson and Company, Eli Lilly and Company, Teva pharmaceuticals, Johnson & Johnson, and Antares Pharma, are some of the leading players in the global autoinjectors market. Companies are working on developing new strategies such as product launch that should contribute to the market growth during the forecast period.
 

Influence of COVID-19 pandemic on the autoinjectors industry landscape

COVID-19 pandemic has disrupted healthcare operations, yet the autoinjectors business has continued to grow significantly in terms of revenue. The demand for autoinjectors was influenced by the rising incidence rate of various respiratory problems among COVID-19 patients. These autoinjectors assist patients in administering a regular dose of medication, which became particularly popular during the COVID-19 pandemic when medical facilities were overrun with infected patients.
 

The autoinjector market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

By Type

  • Disposable
  • Reusable

By Route of Administration

  • Subcutaneous
  • Intramuscular

By Therapy

  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Anaphylaxis
  • Diabetes
  • Oncology
  • Asthma
  • Migraine
  • Hormone Therapy
  • Others

By End-use

  • Hospital & Clinics
  • Homecare Settings
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • Others

 

Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market share for autoinjectors was accounted at more than USD 55 billion in 2022 and is expected to record over 13% CAGR from 2023 to 2032.

Autoinjectors market share from the anaphylaxis therapy segment is forecasted to reach over USD 10 billion by end of 2032 owing to the rising prevalence and occurrence of anaphylaxis and food allergies.

Middle East & Africa autoinjectors industry is expected to reach over USD 12 billion by 2032 owing to the significant investments made in the development of new products by regional manufacturers.

AbbVie Inc., GlaxoSmithKline Plc., Mylan, Amgen, Becton, Ypsomed, Dickinson and Company, Eli Lilly and Company, Johnson & Johnson, and Antares Pharma, are some of the leading companies in the autoinjectors business.

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 10
  • Tables & Figures: 230
  • Countries covered: 15
  • Pages: 175

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount